ZA913359B - Stabilization of somatotropins and other proteins by modification of cysteine residues - Google Patents

Stabilization of somatotropins and other proteins by modification of cysteine residues

Info

Publication number
ZA913359B
ZA913359B ZA913359A ZA913359A ZA913359B ZA 913359 B ZA913359 B ZA 913359B ZA 913359 A ZA913359 A ZA 913359A ZA 913359 A ZA913359 A ZA 913359A ZA 913359 B ZA913359 B ZA 913359B
Authority
ZA
South Africa
Prior art keywords
proteins
polypeptides
cysteine residues
somatotropins
stabilization
Prior art date
Application number
ZA913359A
Other languages
English (en)
Inventor
Brian Lee Buckwalter
Lee Buckwalter Brian
Susan Mancini Cady
Mancini Cady Susan
Michael Joseph Daley
Joseph Daley Michael
Hong-Ming Shieh
Shieh Hong-Ming
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA913359B publication Critical patent/ZA913359B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA913359A 1990-05-04 1991-05-03 Stabilization of somatotropins and other proteins by modification of cysteine residues ZA913359B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51904790A 1990-05-04 1990-05-04

Publications (1)

Publication Number Publication Date
ZA913359B true ZA913359B (en) 1992-03-25

Family

ID=24066559

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913359A ZA913359B (en) 1990-05-04 1991-05-03 Stabilization of somatotropins and other proteins by modification of cysteine residues

Country Status (17)

Country Link
EP (1) EP0458064B1 (ko)
JP (1) JPH069696A (ko)
KR (1) KR100213455B1 (ko)
AT (1) ATE163431T1 (ko)
AU (1) AU639324B2 (ko)
CA (1) CA2041742A1 (ko)
DE (1) DE69128944T2 (ko)
DK (1) DK0458064T3 (ko)
ES (1) ES2113354T3 (ko)
FI (1) FI912144A (ko)
GR (1) GR3026436T3 (ko)
IE (1) IE911511A1 (ko)
IL (1) IL97932A (ko)
NO (1) NO911752L (ko)
NZ (1) NZ237959A (ko)
PT (1) PT97539B (ko)
ZA (1) ZA913359B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB9100381D0 (en) * 1991-01-09 1991-02-20 Erba Carlo Spa Human bfgf derivatives,their analogs and process for their production
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
JP2704214B2 (ja) * 1991-12-10 1998-01-26 タノックス バイオシステムズ インコーポレイテッド 非対合システイン残基を有するサイトカイン及びその結合体
AU6048294A (en) * 1992-11-25 1994-06-22 Amgen Boulder Inc. Modified insulin-like growth factors
EP0622394A1 (en) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
WO2001087925A2 (en) 2000-05-16 2001-11-22 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
KR101238517B1 (ko) 2002-12-26 2013-02-28 마운틴 뷰 파마슈티컬즈, 인크. 생물학적 효능이 향상된 인터페론-베타의 중합체 접합체
CN100580087C (zh) * 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2007041614A2 (en) 2005-10-03 2007-04-12 Bolder Biotechnology, Inc. Long acting vegf inhibitors and methods of use
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
MX345736B (es) * 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質,その製造法および中間体
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof

Also Published As

Publication number Publication date
NZ237959A (en) 1994-05-26
EP0458064A2 (en) 1991-11-27
DE69128944T2 (de) 1998-06-25
NO911752D0 (no) 1991-05-03
AU7607591A (en) 1991-11-07
KR910020032A (ko) 1991-12-19
AU639324B2 (en) 1993-07-22
DK0458064T3 (da) 1998-04-27
EP0458064B1 (en) 1998-02-25
EP0458064A3 (en) 1992-06-17
PT97539A (pt) 1992-02-28
NO911752L (no) 1991-11-05
CA2041742A1 (en) 1991-11-05
PT97539B (pt) 1998-08-31
KR100213455B1 (ko) 1999-08-02
ATE163431T1 (de) 1998-03-15
JPH069696A (ja) 1994-01-18
IE911511A1 (en) 1991-11-06
IL97932A0 (en) 1992-06-21
DE69128944D1 (de) 1998-04-02
FI912144A0 (fi) 1991-05-03
GR3026436T3 (en) 1998-06-30
ES2113354T3 (es) 1998-05-01
IL97932A (en) 1998-02-22
FI912144A (fi) 1991-11-05

Similar Documents

Publication Publication Date Title
ZA913359B (en) Stabilization of somatotropins and other proteins by modification of cysteine residues
DE69027989D1 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
AU4020289A (en) Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis of chemical derivatization
DE3675083D1 (de) Material zum ausfuellen von periodontalen knochendefekten.
EP0564739A3 (ko)
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
PT81441A (en) Process for the prepration of novel polypeptides useful as ana lgesics
IL84484A0 (en) T-cell suppressor protein in pure form,its preparation by recombinant methods and pharmaceutical compositions containing it
HUT46709A (en) Process for producing cyclic peptides and pharmaceutical compositions containing them as active components
NZ234501A (en) Hemoregulatory peptides and pharmaceutical compositions containing them
BR9307687A (pt) Análogos de insulina
IN172427B (ko)
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
PT78571A (en) Process for preparing biologically active polypeptides and of pharmaceutical compositions containing the same
SE8200757L (sv) Biologiskt aktiva peptider
HUT52522A (en) Process for producing imidazol-substituted peptide derivatives and pharmaceutical compositions containing them as active components
DE3667472D1 (de) Analoge von hypokalzemischen polypeptiden, welche den kalziumgehalt des koerpers schonen, deren herstellung, deren verwendung als arznei und diese enthaltende zusammensetzungen.
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
NO873751L (no) Lymfocytt-aktiverende polypeptider.
AU2125088A (en) Solubilization of proteins for pharmaceutical compositions